Leerink Partnrs Has Negative Outlook of Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for Hologic in a report released on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the medical equipment provider will earn $1.02 per share for the quarter, down from their prior forecast of $1.03. The consensus estimate for Hologic’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Hologic’s Q3 2025 earnings at $1.08 EPS and FY2026 earnings at $4.74 EPS.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 20.11%. Hologic’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.89 earnings per share.

HOLX has been the subject of several other research reports. Royal Bank of Canada boosted their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday. Stephens restated an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Finally, StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.25.

Hologic Trading Up 2.1 %

Shares of NASDAQ:HOLX opened at $80.49 on Wednesday. The company has a market cap of $18.70 billion, a P/E ratio of 24.17, a P/E/G ratio of 3.03 and a beta of 0.98. The stock’s 50-day moving average is $81.05 and its 200-day moving average is $78.11. Hologic has a 52-week low of $66.93 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Innealta Capital LLC bought a new stake in shares of Hologic in the 2nd quarter worth about $25,000. Wolff Wiese Magana LLC acquired a new position in Hologic in the third quarter valued at about $25,000. iA Global Asset Management Inc. bought a new stake in Hologic during the first quarter worth about $37,000. Sunbelt Securities Inc. acquired a new stake in shares of Hologic during the second quarter worth approximately $37,000. Finally, Cromwell Holdings LLC raised its stake in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.